Kiran Rajasenan
Hematology & Oncology · Wexford, PANPI 1881667525
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,375 of the $6,613 with a category attached, or 66.2%. 11 manufacturers reported payments, led by AstraZeneca at 42.0% of the total. Reporting peaked in 2021 at $1,897 and has fallen 99.1% since, to $16 in 2024.
Across 16 payments — averaging $413.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Dendreon Pharmaceuticals LLC$2K
- Secura Bio, Inc.$2K
- Johnson & Johnson$240
- Comsort, Inc$100
- Foundation Medicine, Inc.$98
- plus $166 from 5 others
Across 5 payments — averaging $13,614 each. An ownership or investment interest held by the physician or an immediate family member.
- Reflexion Medical, Inc.$68K
What the payments were for
- Consulting fees$4,37566%
- Speaking & faculty fees$1,59824%
- Food & beverage$6029%
- Education$371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $2,775 |
| Dendreon Pharmaceuticals LLC | 2 | $1,635 |
| Secura Bio, Inc. | 2 | $1,598 |
| Johnson & Johnson | 2 | $240 |
| Comsort, Inc | 1 | $100 |
| Foundation Medicine, Inc. | 1 | $98 |
| Bristol Myers Squibb | 1 | $78 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$2,775
- PROVENGE$1,635
- FARYDAK$1,500
- Monarch Platform$240
- KEYTRUDA$100
How this compares
$6,613 in reported general payments places this provider in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 32 | $552,323 |
| RevlimidLenalidomide | 27 | $537,115 |
| TagrissoOsimertinib Mesylate | 23 | $387,653 |
| PomalystPomalidomide | 14 | $316,968 |
| ImbruvicaIbrutinib | 18 | $315,790 |
| CalquenceAcalabrutinib Maleate | 19 | $292,299 |
| Abiraterone Acetate | 58 | $223,903 |
| XtandiEnzalutamide | 15 | $215,838 |
| BrukinsaZanubrutinib | 13 | $193,945 |
| JakafiRuxolitinib Phosphate | 11 | $193,384 |
| NinlaroIxazomib Citrate | 13 | $169,563 |
| LynparzaOlaparib | 11 | $164,353 |
| GleevecImatinib Mesylate | 11 | $107,412 |
| EliquisApixaban | 68 | $51,955 |
| Enoxaparin Sodium | 45 | $17,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence, Lynparza | $2,775 | $844,30553 claims |
| Bristol Myers SquibbRevlimid | $78 | $537,11527 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $15 | $169,56313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Wexford
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.